An Evaluation of Products & Technologies for Molecular Diagnostic within Oncology
HBS Consulting
May 5, 2006 160 Pages - SKU: HBSC1284135
|
|
This latest Multi Client Publication from HBS Consulting provides:
- An overview of current industry-landscape for molecular diagnostics within the oncology area
- Analysis of the key European markets including forecasts for growth, drivers and restraints in the marketplace
- Reimbursement and legislation environment, the most relevant national guidelines relating to genetic testing
- Understanding of market opportunities for molecular diagnostics within the oncology market as an area of growth, research and future developments
The primary objective of this research project is to develop an overview of the molecular diagnostic market for selected oncology markers in the country markets listed further below. The following key issues have been addressed:
- Provide a reflective picture of the type and number of relevant testing institutions
- Which and how many parameters are tested (market size)
- What assays are used (home brew or commercial)
- Market growth per parameter
- Expected market growth rates per parameter in the next 5 years
- What technologies are used (PCR, RT-PCR, FISH, sequencing, micro arrays, others)
- Devices used
- The regulatory issues per country (legislation, reimbursement etc.)
- Future trends & emerging technologies
|
- Introduction
- Project Objectives
- Methodology
- Analysis
- Geographic Scope
- Summary Respondent Population
- Part 1- France
- 1. Current Situation
- 1.1 Respondent Population France
- 1.2 Nucleic Acid Based Testing
- 1.3 Genetic Testing - Routine or Research
- 1.4 HPV Testing
- 1.5 Oncology Markers
- 1.5.1 Solid Tumor Marker
- 1.5.2 Lymphoid Tumour Marker
- 1.6 Nucleic Acid Sample Preparation
- 1.7 Trends in NA-Based Oncology Diagnostics
- 1.7.1 Emerging Markers
- 1.7.2 CE approval
- 1.8 NAT - application and technical appraisal
- 1.9 Politics and Reimbursement
- 1.9.1 Drivers of NAT
- 1.9.2. Restraints on NAT
- 1.10 Summary and Conclusions
- Part 2 - Germany
- 2. Current Situation
- 2.1 Respondent Population Germany
- 2.2 Nucleic Acid Based Testing
- 2.3 Genetic Testing - Routine or Research
- 2.4 HPV Testing
- 2.5 Oncology Markers
- 2.5.1 Solid Tumor Marker
- 2.5.2 Lymphoid Tumor Marker
- 2.6 Nucleic Acid Sample Preparation
- 2.7 Trends in Genetics Based Oncology Diagnostics
- 2.7.1 Emerging Markers
- 2.7.2 CE certification
- 2.8 NAT - application and technical appraisal
- 2.9 Politics and Reimbursement
- 2.9.1 Drivers of NAT
- 2.9.2 Restraints on NAT
- 2.10 Summary and Conclusions
- Part 3 - Italy
- 3. Current Situation
- 3.1. Respondent Population - Italy
- 3.2 Nucleic Acid Based Testing
- 3.2.1 Types of testing performed
- 3.3 Genetic Testing - Routine or Research
- 3.4 HPV Testing
- 3.5 Oncology Markers
- 3.5.1 Solid Tumor Marker
- 3.5.2. Lymphoid Tumor Marker
- 3.6 Nucleic Acid Sample Preparation
- 3.7 Trends in NA-Based Oncology Diagnostics
- 3.7.1 Emerging Markers
- 3.7.2 CE or FDA approval
- 3.8 NAT - application and technical appraisal
- 3.9 Politics and Reimbursement
- 3.9.1 Drivers of NAT
- 3.9.2 Restraints on NAT
- 3.10 Summary and Conclusions
- Part 4 - UNITED KINGDOM
- 4. Current Situation
- 4.1 Respondent Population UK
- 4.2 Nucleic Acid Based Testing
- 4.3 Genetic Testing - Routine or Research
- 4.4 HPV Testing
- 4.5 Oncology Markers
- 4.5.1 Solid Tumor Marker
- 4.5.2 Lymphoid Tumor Marker
- 4.6 Nucleic Acid Sample Preparation
- 4.7 Trends in NA-Based Oncology Diagnostics
- 4.7.2 Emerging Markers
- 4.7.3 CE certification
- 4.8 NAT - application and technical appraisal
- 4.9 Politics and Reimbursement
- 4.9.1 Drivers of NAT
- 4.9.2 Restraints on NAT
- 4.10 Summary and Conclusions
- Part 5 - USA
- 5. Current Situation
- 5.1 Respondent Population US
- 5.2 Nucleic Acid Based Testing
- 5.2.1 Types of testing performed
- 5.3 Genetic Testing - Routine or Research
- 5.4 HPV Testing
- 5.5 Oncology Markers
- 5.5.1 Solid Tumor Marker
- 5.5.2 Lymphoid Tumor Marker
- 5.6 Nucleic Acid Sample Preparation
- 5.7 Trends in NA-Based Oncology Diagnostics
- 5.7.1 Emerging Marker
- 5.7.2 Test Certification
- 5.8 NAT - application and technical appraisal
- 5.9 Politics and Reimbursement
- 5.9.1 Drivers of NAT
- 5.9.2 Restraints on NAT
- 5.10 Summary and Conclusions
- Abbreviations & Definitions
Share this report
Other tasks Related Markets Oncology/Hematology Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
